Released Nov 5, 2020, after the close
10-Q filed Nov 5, 2020, 36 days after period end · 0001564590-20-051279
Q3 2020 · 10-Q
Revenue$38.00K$38.00K −77.9% vs Q3 2019−25.5% vs Q2 2020
Net Income-$18.90M-$18.90M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.86-$0.86 N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$19,020,000N/M
Operating Cash Flowderived-$21,264,000N/M
Free Cash Flowderived-$21,315,000N/M
Margins · derived
Operating margin-50052.6%−39596.2 pt vs Q3 2019
Net margin-49736.8%−39446.1 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $38.00K | $172.00K | $658.00K | $597.00K |
| Net Income | -$18.90M | -$17.70M | -$10.46M | -$9.84M |
| EPS Diluted | -$0.86 | -$0.95 | -$0.60 | -$36.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR